Skip to main content
Clinical Trials/NCT01767428
NCT01767428
Completed
Phase 1

A Pharmacokinetic Study to Evaluate the Rate and Extent of Absorption of Paracetamol From Two Formulations in an Indian Population.

GlaxoSmithKline0 sites30 target enrollmentApril 2010

Overview

Phase
Phase 1
Intervention
Paracetamol
Conditions
Fever
Sponsor
GlaxoSmithKline
Enrollment
30
Primary Endpoint
Cmax
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

A pharmacokinetic study in healthy volunteers comparing two formulations of paracetamol fast release in fasted state.

Registry
clinicaltrials.gov
Start Date
April 2010
End Date
April 2010
Last Updated
13 years ago
Study Type
Interventional
Study Design
Crossover
Sex
Male

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Healthy male volunteers aged 18-55yrs willing to give written informed consent for the study
  • BMI must be within the range 18.5 - 24.9 kg/m\^2
  • Participant with a minimum weight of 50 kg

Exclusion Criteria

  • Participant with current or recurrent disease that could affect the action, absorption or disposition of the study medication or clinical or laboratory assessments (e.g. hepatic disorders, renal insufficiency, congestive heart failure)
  • Participant with known or suspected intolerance or hypersensitivity to the study materials
  • Participant who are vegetarian
  • Participant smoking more than five cigarettes a day

Arms & Interventions

Experimental Paracetamol Tablet

Experimental paracetamol tablet (500 milligrams \[mg\]) administered with 240 milliliters (mL) of water.

Intervention: Paracetamol

Standard Paracetamol Tablet (500 mg)

Standard paracetamol tablet (500 mg) administered with 240 mL of water.

Intervention: Paracetamol

Outcomes

Primary Outcomes

Cmax

Time Frame: Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose.

Maximum plasma concentration of paracetamol.

AUC (0-t)

Time Frame: Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose.

Area under the plasma concentration time curve from zero and extrapolated to the time of last quantifiable sample.

AUC (0-inf)

Time Frame: Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose.

Area under the plasma concentration time curve from zero and extrapolated to infinite time.

Secondary Outcomes

  • Tmax(Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose.)

Similar Trials